Irene Haralabatos, MD
Allergy & Immunology · Philadelphia, PANPI 1386792430
Payments from drug & device makers
Across 543 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Optinose US, Inc.$865
- Takeda Pharmaceuticals U.S.A., Inc.$752
- Sanofi$728
- CSL Behring$642
- plus $3K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $1,965 |
| AstraZeneca | 70 | $1,322 |
| Optinose US, Inc. | 59 | $865 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $752 |
| Sanofi | 42 | $728 |
| CSL Behring | 36 | $642 |
| Regeneron Healthcare Solutions, Inc. | 38 | $630 |
| Kaleo, Inc. | 22 | $396 |
| Biocryst US Sales Co., LLC | 13 | $285 |
| Pfizer | 22 | $281 |
| Novartis | 17 | $256 |
| Genentech USA, Inc. | 12 | $217 |
| Boehringer Ingelheim | 9 | $200 |
| Blueprint Medicines Corporation | 5 | $126 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| Shire North American Group Inc | 5 | $87 |
| Grifols USA, LLC | 3 | $85 |
| Amgen | 4 | $72 |
| Bio Products Laboratory USA, Inc. | 5 | $71 |
| Covis Pharma GmbH | 4 | $52 |
| Merck | 3 | $45 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $43 |
| Aytu Biopharma, Inc. | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Octapharma USA, Inc. | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Organon | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
How this compares
$9,412 in reported general payments places this provider in the 65th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$15.3M
- Rahul DattaPhiladelphia$198K
- Arnold LevinsonPhiladelphia$95K
- John BossoPhiladelphia$86K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Donald DvorinPhiladelphia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.